Cerezyme (imiglucerase) er indiceret til brug som langvarig enzymerstatningsbehandling hos patienter med en bekræftet diagnose lydende på ikke- neuronopatisk (Type 1) eller kronisk neuronopatisk (Type 3) Gauchers sygdom, der udviser klinisk signifikante, ikke- neurologiske manifestationer af sygdommen.
Cerezyme (imiglucerase) is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease and who exhibit clinically significant non-neurological manifestations of the disease.